Clinical Trials Browser

Head and Neck Neoplasms, Nasopharyngeal Neoplasms

NCT06851663 2026-05-29

Trop2-targeted immunoPET Imaging of Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Clinical Trials

EDS01 HN

Trop2-targeted immunoPET Imaging of Solid Tumors

SG-AAA-II-01

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

ACUPUNCTURE

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

ALTER-HN005

Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma

REDEFINE

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma

Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Impact of Vitamin D on Therapeutic Respons in NPC Chemoradiated Patients

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

NIVONASO-21

Influence of the "Hypotension Probability Index" on Intraoperative and Postoperative Hypotension in ENT- and OM-Surgery

GEMSTONE

Adebrelimab and Chemoradiotherapy in High-risk LANPC

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

2018/00947

Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study

NPC-Nivo

The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma

DIPPER

3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

CONTINUUM

Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

CRCSTNPC

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma